OurCrowd Portfolio Company Alpha Tau Medical Seeks New Cancer Treatment, Shares Results of Trial Radiotherapy

OurCrowd portfolio company Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Alpha Tau Medical has recently shared results of a clinical trial of its cancer treatment in the International Journal of Radiation Oncology, Biology, and Physics, the official journal of the American Society for Radiation Oncology

The objectives of the trial were to establish the feasibility, safety, and efficacy of Alpha DaRT for the management of patients with squamous cell carcinoma of the skin and head and neck region. Reportedly, all 28 evaluable treated lesions underwent successful placement of the “Alpha DaRT seeds,” and there were no severe toxicities noted.

The principal investigator of the Israeli arm of the trial, radiation oncologist Prof. Aron Popovtzer, MD, from Rabin Medical Center in Israel, commented on the trial:

“The results we obtained from our first clinical trial in human squamous cell carcinoma patients confirm the promising findings from preclinical studies. The observed tumor response rates and survival metrics seem especially impressive given this elderly (median age 80.5 years) and heavily pretreated patient sample. Overall, these impressive outcomes serve as an excellent basis for future trials in other tumor types.”

OurCrowd is the leading investment crowdfunding platform in the world with over $1.3 billion in capital commitments and over a dozen exits since platform launch.


Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote

Send this to a friend